Dianthus Therapeutics, Inc. (DNTH) is the issuer in a Schedule 13G reporting that Vanguard Capital Management beneficially owned 2,846,786 common shares, equal to 5.08% of the class. The reported amount includes securities held by Vanguard funds over which Vanguard Capital Management exercises dispositive power, and client securities subject to voting and/or dispositive power exercised by named affiliates or divisions. Vanguard reported sole voting power over 418,713 shares and sole dispositive power over 2,846,786 shares; shared voting and dispositive power were each 0 shares. My Trieu-Gatt signed as Authorized Signatory, Head of Global Fund Administration.
Dianthus Therapeutics, Inc. (DNTH) reported that its Chief Accounting Officer, Edward Carr, exercised options for 20,000 shares of common stock on September 17, 2026 at an exercise price of $17.88 per share and sold the same 20,000 shares in multiple market transactions on that date. The company reports that the options exercise and related sales were made under a Rule 10b5-1 trading plan adopted by Mr. Carr on June 18, 2026, and that he held 43,818 stock options after the exercise.
Dianthus Therapeutics, Inc. (DNTH) has filed an automatic shelf registration on Form S-3 as a well-known seasoned issuer and, under it, established an at-the-market offering program to sell up to $500,000,000 of common stock through TD Cowen. The base shelf also permits future offerings of an indeterminate amount of common stock, preferred stock, debt securities, warrants and units. Common stock outstanding was 54,798,338 shares as of June 30, 2026, and the last reported price was $101.12 per share on September 17, 2026. The company intends to use proceeds primarily to fund preclinical and clinical development, along with working capital and other general corporate purposes, with potential use for in-licensing or acquiring product candidates.
Dianthus Therapeutics, Inc. (DNTH) officer Edward Carr filed a notice of proposed sale of securities under Rule 144. The filing covers up to 20,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, arising from an exercise of stock options for cash on September 17, 2026. The shares have an indicated aggregate market value of $2,049,800. Shares of Dianthus common stock were listed on NASDAQ, with 55,934,378 shares outstanding on the referenced date as a baseline figure, not the amount being sold.
Dianthus Therapeutics, Inc. (DNTH) executive Simrat Randhawa, EVP and Head of R&D, reported an exercise-and-sell transaction on September 1, 2026. Randhawa exercised stock options for 23,124 shares of common stock at exercise prices of $17.88, $21.77, and $22.07 per share, then sold 23,124 shares of common stock in multiple open-market transactions at weighted average prices around $105–$107 per share. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 14, 2025. The options exercised relate to awards that vest in equal monthly installments over four years beginning January 1, 2024, May 1, 2024, and January 1, 2025, respectively.
Dianthus Therapeutics, Inc. (DNTH) is the issuer for a notice filed by officer Simrat Randhawa under Rule 144 to potentially sell up to 23,124 shares of common stock through Morgan Stanley Smith Barney LLC on or after 09/01/2026 on NASDAQ. The shares are to be acquired via exercise of stock options for cash from the issuer. The notice lists an aggregate market value of $2,442,125.64 for the securities covered and indicates 55,934,378 shares of common stock outstanding.
Dianthus Therapeutics, Inc. (DNTH) director Simon Read reported an option exercise-and-sale on common stock. He exercised 2,778 stock options at an exercise price of $18.36 per share, acquiring 2,778 shares of common stock, and on the same date sold 2,778 shares at a weighted-average price of $117.55 per share. The option exercise left 19,445 options reported as outstanding after the transaction, with the option expiring on May 22, 2035. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026, and the option award vests in three equal annual installments, subject to continued service.
Dianthus Therapeutics, Inc. insider activity: Adam M. Veness, SVP, General Counsel and Secretary, reported exercising stock options for 15,000 shares of common stock on August 13, 2026 at an exercise price of $18.17 per share. This converted a stock option into directly held common shares.
The derivative position of 15,000 option shares was disposed of upon exercise, leaving Veness with 73,240 derivative securities reported following the transaction. The option award vested 25% on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to his continued service.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 1,696,751 shares of Dianthus Therapeutics, Inc. common stock, including 510,400 shares issuable upon exercise of call options. This represents 3.1% of the company’s 54,666,233 shares outstanding as of May 1, 2026.
The reporting persons have shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing is an amendment to a Schedule 13G and confirms ownership of less than 5% of the class.
Dianthus Therapeutics, Inc. has a significant shareholder group led by Wellington Management entities, which report passive beneficial ownership of its common stock. Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP collectively report beneficial ownership of 3,229,882 shares of common stock, representing approximately 5.9–5.91% of the class.
These shares are held of record by clients of various Wellington investment advisers. The Wellington filers report 0 shares with sole voting or dispositive power, and only shared voting and dispositive power over the reported shares. No individual client is reported to have rights over more than five percent of the class.